- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
Sunday, June 4, 2006
 |
OncoLink coverage of the Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, in Atlanta, GA OncoLink reporters provide in-depth, up-to-the-minute coverage of sessions and presentations.
|
A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)
Presenter: Gary HudesPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PAType of Session: PlenaryBackground Several recent advances in the treatment of advanced RCC using targeted therapy have been made Sorafenib, a... |
|
|
Induction cisplatin (P) and fluorouracil (F) with or without docetaxel (T) followed by chemoradiation (CTRT) and surgical resection as indicated for locally advanced squamous cell carcinoma (LASCC) of the head & neck: preliminary results from the TAX 324 study
Presenter: Posner MRPresenter's Affiliation: Dana-Farber Cancer Institute, Boston, MAType of Session: ScientificBackground PF induction chemotherapy has thus far proven to be the sole induction chemotherapeutic regimen to be effective in... |
|
|
Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal
Presenter: J.A. AjaniPresenter's Affiliation: M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground The current standard treatment of squamous cell carcinoma of the anus is concurrent chemoradiation (CRT) with 5-FU and... |
|
|
Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study.
Presenter: P. PaschkaPresenter's Affiliation: Ohio State University, Columbus, OHType of Session: PlenaryBackground Core binding factor acute myeloid leukemia (CBF AML) is a specific subtype of leukemia. CBF AML has 2 of the most... |
|
|
Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma
Presenter: U. GatzemeierPresenter's Affiliation: Hospital Grosshansdorf, Grosshansdorf/Hamburg, GermanyType of Session: ScientificBackground The Raf/MEK/ERK pathway is an attractive target in NSCLC 20% Ras mutations which are... |
|
|
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
Presenter: Robert J. MotzerPresenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NYType of Session: PlenaryBackground Clear cell renal cell carcinoma (RCC) is characterized by mutation or silencing of the VHL gene, which in... |
|
|
Phase III trial of intermittent MAB vs continuous MAB
Presenter: F.M. Calais Da SilvaPresenter's Affiliation: Hospital Desterro, Lisbon, PortugalType of Session: ScientificBackground Androgen deprivation relieves symptoms and causes a reduction of PSA level in men with locally advanced and... |
|
|
Postoperative concurrent radiochemotherapy (RCT) versus radiotherapy (RT) in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96-3
Presenter: Fietkau RPresenter's Affiliation: University of Rostock, Rostock, GermanyType of Session: ScientificBackground Characteristics of high-risk SCCA of the head and neck on surgical pathology include, but are not limited to, involvement... |
|
|
Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
Presenter: A.J. Stephenson Presenter's Affiliation: Cleveland Clinic, Cleveland, OH Type of Session: Keynote Background Following radical prostatectomy, 25% of patients experience a rising PSA. Risk factors for metastatic disease... |
|
|
Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01
Presenter: Calais GPresenter's Affiliation: Centre Henry S. Kaplan, Tours, FranceType of Session: ScientificBackground Induction chemotherapy followed by radiation treatment (RT) provides a potential for functional laryngeal preservation in... |
|
|
RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma
Presenter: William F. ReginePresenter's Affiliation: University of Maryland, Baltimore, MDType of Session: ScientificBackground Adenocarcinoma of the pancreas, even when resectable, has a poor prognosis. Failures occur both locoregionally... |
|
|
Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP or autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma (MM)
Presenter: Facon TPresenter's Affiliation: CHU, Lille, FranceType of Session: PlenaryBackground MP is the standard treatment for newly diagnosed elderly patients with MM, conferring a median overall survival (OS) of 3 years THAL has... |
|
|
The impact of FLIPI on outcome of frontline treatment with single-agent I-131 tositumomab for follicular lymphoma (FL)
Presenter: M.S. Kaminski Presenter's Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MI Type of Session: Scientific Background Follicular lymphoma is an indolent Non-Hodgkin's lymphoma that usually presents in an... |
|
|
The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation.
Presenter: A.J.Al-Tourah Presenter's Affiliation: BC Cancer Agency Fraser Valley Centre, Surrey, BC, Canada Type of Session: Keynote Background Follicular lymphoma is an indolent Non-Hodgkin's lymphoma that usually presents in an advanced... |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
